These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 16018174)
21. First trimester Down's syndrome screening shows high detection rate for trisomy 21, but poor performance in structural abnormalities--regional outcome results. Rissanen A; Niemimaa M; Suonpää M; Ryynänen M; Heinonen S Fetal Diagn Ther; 2007; 22(1):45-50. PubMed ID: 17003556 [TBL] [Abstract][Full Text] [Related]
22. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509 [TBL] [Abstract][Full Text] [Related]
23. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Stenhouse EJ; Crossley JA; Aitken DA; Brogan K; Cameron AD; Connor JM Prenat Diagn; 2004 Oct; 24(10):774-80. PubMed ID: 15503268 [TBL] [Abstract][Full Text] [Related]
24. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Spencer K; Bindra R; Cacho AM; Nicolaides KH Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947 [TBL] [Abstract][Full Text] [Related]
26. Serum PAPP-A levels at 10-14 weeks of gestation are altered in women after assisted conception. Tul N; Novak-Antolic Z Prenat Diagn; 2006 Dec; 26(13):1206-11. PubMed ID: 17075793 [TBL] [Abstract][Full Text] [Related]
27. [Maternal biochemical screening -- an approach for genetic prevention. part 1. first and second trimester screening]. Angelova L; Gadancheva V; Konstantinova D; Stoianova M; Hachmerian M; Yakov B; Kremenski I Akush Ginekol (Sofiia); 2013; 52(5):8-13. PubMed ID: 24501862 [TBL] [Abstract][Full Text] [Related]
30. [Nuchal translucency and combined test: what are the implications in clinical practice?]. Marchini G; Rosati A; Ribiani E; Romanelli M; Porcaro G; Clerici G Minerva Ginecol; 2010 Jun; 62(3):187-93. PubMed ID: 20595943 [TBL] [Abstract][Full Text] [Related]
31. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency. Bestwick JP; Huttly WJ; Wald NJ J Med Screen; 2008; 15(4):204-6. PubMed ID: 19106261 [TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Scott F; Peters H; Bonifacio M; McLennan A; Boogert A; Kesby G; Anderson J Aust N Z J Obstet Gynaecol; 2004 Jun; 44(3):205-9. PubMed ID: 15191443 [TBL] [Abstract][Full Text] [Related]
37. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening. Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371 [TBL] [Abstract][Full Text] [Related]
38. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Spencer K; Cowans NJ; Avgidou K; Nicolaides KH Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214 [TBL] [Abstract][Full Text] [Related]
39. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. Spencer K; Nicolaides KH BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267 [TBL] [Abstract][Full Text] [Related]